{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T07:35:33Z","timestamp":1740123333694,"version":"3.37.3"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,1,28]],"date-time":"2019-01-28T00:00:00Z","timestamp":1548633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2019,1,28]],"date-time":"2019-01-28T00:00:00Z","timestamp":1548633600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2019,6,15]]},"DOI":"10.1007\/s10637-019-00725-3","type":"journal-article","created":{"date-parts":[[2019,1,28]],"date-time":"2019-01-28T03:18:09Z","timestamp":1548645489000},"page":"524-530","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The influence of prior ramucirumab treatment on the clinical activity of FOLFIRI as third-line therapy in patients with metastatic gastric Cancer"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5504-8237","authenticated-orcid":false,"given":"Giandomenico","family":"Roviello","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Petrioli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pietro","family":"Rosellini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea Giovanni","family":"Multari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raffaele","family":"Conca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Paganini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgio","family":"Chiriac\u00f2","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Aieta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,1,28]]},"reference":[{"issue":"1","key":"725_CR1","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s10120-016-0615-3","volume":"20","author":"G De Manzoni","year":"2017","unstructured":"De Manzoni G, Marrelli D, Baiocchi GL, Morgagni P, Saragoni L, Degiuli M et al (2017 Jan) The Italian research Group for Gastric Cancer (GIRCG) guidelines for gastric cancer staging and treatment: 2015. Gastric Cancer 20(1):20\u201330","journal-title":"Gastric Cancer"},{"key":"725_CR2","unstructured":"Marano L, Polom K, Patriti A, Roviello G, Falco G, Stracqualursi A, et al (2015) Surgical management of advanced gastric cancer: An evolving issue. Eur J Surg Oncol. Nov 14."},{"issue":"3","key":"725_CR3","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1245\/s10434-015-4931-3","volume":"23","author":"D Marrelli","year":"2016","unstructured":"Marrelli D, Polom K, Pascale V, Vindigni C, Piagnerelli R, De Franco L, Ferrara F, Roviello G, Garosi L, Petrioli R, Roviello F (2016 Mar) Strong prognostic value of microsatellite instability in intestinal type non-cardia gastric Cancer. Ann Surg Oncol 23(3):943\u2013950","journal-title":"Ann Surg Oncol"},{"issue":"9911","key":"725_CR4","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(13)61719-5","volume":"383","author":"CS Fuchs","year":"2014","unstructured":"Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, Safran H, dos Santos LV, Aprile G, Ferry DR, Melichar B, Tehfe M, Topuzov E, Zalcberg JR, Chau I, Campbell W, Sivanandan C, Pikiel J, Koshiji M, Hsu Y, Liepa AM, Gao L, Schwartz JD, Tabernero J (2014) REGARD Trial Investigators. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. Jan 4 383(9911):31\u201339","journal-title":"Lancet"},{"issue":"11","key":"725_CR5","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","volume":"15","author":"H Wilke","year":"2014","unstructured":"Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, Hironaka S, Sugimoto N, Lipatov O, Kim TY, Cunningham D et al (2014) Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 15(11):1224\u20131235","journal-title":"Lancet Oncol"},{"issue":"13","key":"725_CR6","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1200\/JCO.2011.39.4585","volume":"30","author":"JH Kang","year":"2012","unstructured":"Kang JH, Lee SI, Lim DH, Park KW, Oh SY, Kwon HC et al (2012) Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive carealone. Clin Oncol 30(13):1513\u20131518","journal-title":"Clin Oncol"},{"issue":"4","key":"725_CR7","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s10120-012-0227-5","volume":"16","author":"EJ Kang","year":"2013","unstructured":"Kang EJ, Im SA, Oh DY, Han SW, Kim JS, Choi IS et al (2013) Irinotecan combined with 5-fluorouracil and leucovorin third-line chemotherapy afterfailure of fluoropyrimidine, platinum, and taxane in gastric cancer: treatment outcomes and a prognostic model to predict survival. Gastric Cancer 16(4):581\u2013589","journal-title":"Gastric Cancer"},{"issue":"2","key":"725_CR8","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R et al (2009 Jan) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228\u2013247","journal-title":"Eur J Cancer"},{"key":"725_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","volume":"10","author":"R Simon","year":"1989","unstructured":"Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1\u201310","journal-title":"Control Clin Trials"},{"key":"725_CR10","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.critrevonc.2017.05.002","volume":"116","author":"WL Chana","year":"2017","unstructured":"Chana WL, Yuen KK, Siu S, Lamb K, Kwong DL (2017) Third-line systemic treatment versus best supportive care for advanced\/metastatic gastric cancer: a systematic review and meta-analysis. Crit Rev Oncol Hematol 116:68\u201381","journal-title":"Crit Rev Oncol Hematol"},{"issue":"13","key":"725_CR11","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1200\/JCO.2015.63.5995","volume":"34","author":"J Li","year":"2016","unstructured":"Li J, Qin S, Xu J, Xiong J, Wu C, Bai Y et al (2016) Randomized, double-blind,placebo-controlled phase III trial of apatinib in patients withchemotherapy-refractory advanced or metastatic adenocarcinoma of thestomach or gastroesophageal junction. J Clin Oncol 34(13):1448\u20131454","journal-title":"J Clin Oncol"},{"key":"725_CR12","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.critrevonc.2016.04.001","volume":"102","author":"R Petrioli","year":"2016","unstructured":"Petrioli R, Roviello G, Zanotti L, Roviello F, Polom K, Bottini A, Marano L, Francini E, Marrelli D, Generali D (2016 Jun) Epirubicin-based compared with docetaxel-based chemotherapy for advanced gastric carcinoma: a systematic review and meta-analysis. Crit Rev Oncol Hematol 102:82\u201388","journal-title":"Crit Rev Oncol Hematol"},{"key":"725_CR13","doi-asserted-by":"publisher","unstructured":"Takahari D (2017 May) Second-line chemotherapy for patients with advanced gastric cancer. Gastric Cancer 20(3):395\u2013406. https:\/\/doi.org\/10.1007\/s10120-017-0707-8 Epub 2017 Mar 4","DOI":"10.1007\/s10120-017-0707-8"},{"issue":"40","key":"725_CR14","doi-asserted-by":"publisher","first-page":"14537","DOI":"10.3748\/wjg.v20.i40.14537","volume":"20","author":"F De Vita","year":"2014","unstructured":"De Vita F, Di Martino N, Fabozzi A, Laterza MM, Ventriglia J, Savastano B, Petrillo A, Gambardella V, Sforza V, Marano L, Auricchio A, Galizia G, Ciardiello F, Orditura M (2014 Oct 28) Clinical management of advanced gastric cancer: the role of new molecular drugs. World J Gastroenterol 20(40):14537\u201314558","journal-title":"World J Gastroenterol"},{"issue":"6","key":"725_CR15","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.ctrv.2014.03.002","volume":"40","author":"F Lordick","year":"2014","unstructured":"Lordick F, Allum W, Carneiro F, Mitry E, Tabernero J, Tan P et al (2014 Jul) Unmet needs and challenges in gastric cancer: the way forward. Cancer Treat Rev 40(6):692\u2013700","journal-title":"Cancer Treat Rev"},{"key":"725_CR16","first-page":"24(e6884)","volume":"96","author":"MM Yu Zheng","year":"2017","unstructured":"Yu Zheng MM, Xu-Qing Zhu BM, XiaoGang Ren MM (2017) Third-line chemotherapy in advanced gastric cancer A systematic review and meta-analysis. Medicine 96:24(e6884)","journal-title":"Medicine"},{"key":"725_CR17","doi-asserted-by":"crossref","unstructured":"Erdem GU, Bozkaya Y, Ozdemir NY, Demirci NS, Yazici O, Zengin N (2018) 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) as a third-line chemotherapy treatment in metastatic gastric cancer, after failure of fluoropyrimidine, platinum, anthracycline, and taxane. Bosn J Basic Med Sci 20;18(2):170\u2013177","DOI":"10.17305\/bjbms.2017.2258"},{"issue":"8","key":"725_CR18","first-page":"887","volume":"10","author":"G Roviello","year":"2016","unstructured":"Roviello G, Ravelli A, Fiaschi AI et al (2016) Apatinib for the treatment of gastric cancer. Expert Review of Gastroenterology & Hepatology 10(8):887\u2013892","journal-title":"Expert Review of Gastroenterology & Hepatology"},{"issue":"26","key":"725_CR19","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.1200\/JCO.2013.48.8585","volume":"31","author":"J Li","year":"2013","unstructured":"Li J, Qin S, Xu J, Guo W, Xiong J, Bai Y et al (2013) Apatinib forchemotherapy-refractory advanced metastatic gastric cancer: results from arandomized, placebo-controlled, parallel-arm, phase II trial. J Clin Oncol 31(26):3219\u20133225","journal-title":"J Clin Oncol"},{"issue":"31","key":"725_CR20","doi-asserted-by":"publisher","first-page":"3935","DOI":"10.1200\/JCO.2012.48.3552","volume":"31","author":"A Ohtsu","year":"2013","unstructured":"Ohtsu A, Ajani JA, Bai YX, Bang YJ, Chung HC, Pan HM et al (2013) Everolimus for previously treated advanced gastric cancer: results of therandomized double-blind phase III GRANITE-1 study. J Clin Oncol 31(31):3935\u20133943","journal-title":"J Clin Oncol"},{"key":"725_CR21","unstructured":"Pavlakis N, Sjoquist KM, Tsobanis E, Martin AJ, Kang Y-K, Bang J, et al (2015) INTEGRATE: a randomized, phase II, double-blind, placebo-controlled study ofregorafenib in refractory advanced oesophagogastric cancer (AOGC): a studyby the Australasian Gastrointestinal Trials Group (AGITG)-final overall andsubgroup results. J. Clin. Oncol., Conference: 2015 Annual Meeting of theAmerican Society of Clinical Oncology, ASCO Chicago, IL United States. Conference Start: 20150529 Conference End: 20150602. ConferencePublication: (var.pagings). 33 (15 SUPPL. 1) (no pagination), 2015. Date ofPublication: 20 May 2015"},{"key":"725_CR22","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3390\/biomedicines6010034","volume":"6","author":"NS Yee","year":"2018","unstructured":"Yee NS (2018) Update in systemic and targeted therapies in gastrointestinal oncology. Biomedicines 6:34","journal-title":"Biomedicines"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-019-00725-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-019-00725-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-019-00725-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T18:32:00Z","timestamp":1678559520000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-019-00725-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,28]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,6,15]]}},"alternative-id":["725"],"URL":"https:\/\/doi.org\/10.1007\/s10637-019-00725-3","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"type":"print","value":"0167-6997"},{"type":"electronic","value":"1573-0646"}],"subject":[],"published":{"date-parts":[[2019,1,28]]},"assertion":[{"value":"3 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Roviello G declares that he has no conflict of interest. Petrioli R declares that he has no conflict of interest. Multari AG declares that he has no conflict of interest. Conca R declares that he has no conflict of interest. Paganini G declares that he has no conflict of interest. Chiariac\u00f2 G declares that he has no conflict of interest. Aieta M declares that he has no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethical approval: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}